Revolution Medicines CFO Jack Anders Sells $6.72M of Stock
Jack Anders, CFO, sold 35,750 shares of Revolution Medicines, Inc. at $181.04 to $192.84 a share (average $188.10) in 11 transactions, worth $6.72M in total on Nov 11, 2026. Shares held after the trade: 119,216 (-7.7%).
Revolution Medicines reported its first product revenue of $197.6 million for the quarter ended September 30, 2026, following the commercialization of RASONQUE® (daraxonrasib). The company significantly strengthened its balance sheet, ending the period with approximately $3.65 billion in cash and marketable securities, though it continues to operate with a substantial accumulated deficit of $4.37 billion.
Revolution Medicines reported financial results for the third quarter of 2026, highlighted by the U.S. commercial launch of RASONQUE (daraxonrasib) for metastatic pancreatic cancer. The product generated $197.6 million in net revenue during its first five weeks on the market, with over 5,000 unique patients treated. The company also received a positive CHMP opinion for the drug in the European Union.
Term
Q3 2026
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.”
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
Revolution Medicines Insider Anthony Mancini Sells $432K of Stock
Anthony Mancini sold 2,310 shares of Revolution Medicines, Inc. at $186.99 a share, worth $432K in total on Oct 26, 2026. Shares held after the trade: 39,765 (-5.5%).
Revolution Medicines $250M Debt Financing with Royalty Pharma Development Funding, LLC
Revolution Medicines drew down a $250 million Tranche A senior secured term loan from Royalty Pharma following the FDA approval of RASONQUE. The loan bears interest at a floating rate of three-month Term SOFR plus 5.75% and is due in full on October 8, 2032. The company also elected not to exercise an option to sell an additional $250 million royalty interest to Royalty Pharma.
Revolution Medicines Chief Development Officer Alan B. Sandler Sells $1.28M of Stock
Alan B. Sandler, Chief Development Officer, sold 6,309 shares of Revolution Medicines, Inc. at $200.82 to $204.72 a share (average $202.14) in 5 transactions, worth $1.28M in total on Sep 29, 2026. Shares held after the trade: 52,559 (-0.6%).
Revolution Medicines Director Elizabeth M. Anderson Sells $1.96M of Stock
Elizabeth M. Anderson, Director, sold 10,143 shares of Revolution Medicines, Inc. at $191.85 to $195.15 a share (average $193.04) in 5 transactions, worth $1.96M in total on Sep 22, 2026. Shares held after the trade: 4,333 (-2.3%).
Revolution Medicines Chief Development Officer Alan B. Sandler Sells $67K of Stock
Alan B. Sandler, Chief Development Officer, sold 336 shares of Revolution Medicines, Inc. at $199.30 a share, worth $67K in total on Sep 16, 2026. Shares held after the trade: 52,868 (-0.6%).
Revolution Medicines Insider Anthony Mancini Sells $348K of Stock
Anthony Mancini sold 1,747 shares of Revolution Medicines, Inc. at $199.30 a share, worth $348K in total on Sep 16, 2026. Shares held after the trade: 42,116 (-4.0%).
Revolution Medicines Insider Stephen Michael Kelsey Sells $1.11M of Stock
Stephen Michael Kelsey sold 5,569 shares of Revolution Medicines, Inc. at $195.01 to $199.30 a share (average $199.24) in 2 transactions, worth $1.11M in total on Sep 16, 2026. Shares held after the trade: 286,307 (-1.9%).
Revolution Medicines COO Margaret A. Horn Sells $990K of Stock
Margaret A. Horn, COO, sold 4,967 shares of Revolution Medicines, Inc. at $195.01 to $199.30 a share (average $199.24) in 2 transactions, worth $990K in total on Sep 16, 2026. Shares held after the trade: 149,680 (-3.2%).
Revolution Medicines Insider Mark A. Goldsmith Sells $2.79M of Stock
Mark A. Goldsmith sold 13,988 shares of Revolution Medicines, Inc. at $195.01 to $199.30 a share (average $199.24) in 2 transactions, worth $2.79M in total on Sep 16, 2026. Shares held after the trade: 253,342 (-5.2%).
Revolution Medicines SVP & General Counsel Jeff Cislini Sells $671K of Stock
Jeff Cislini, SVP & General Counsel, sold 3,366 shares of Revolution Medicines, Inc. at $195.01 to $199.30 a share (average $199.24) in 2 transactions, worth $671K in total on Sep 16, 2026. Shares held after the trade: 52,541 (-5.9%).
Revolution Medicines CFO Jack Anders Sells $808K of Stock
Jack Anders, CFO, sold 4,053 shares of Revolution Medicines, Inc. at $195.00 to $199.30 a share (average $199.24) in 2 transactions, worth $808K in total on Sep 16, 2026. Shares held after the trade: 119,216 (-3.2%).